As a control for this role of KRT19, s/c tumors were formed with PDA cells in which Krt18 had been edited and were observed to be stained with anti-CXCL12 antibody (SI Appendix, Fig. S6 D and E). The gene discussed is CXCL12; the disease is Patent ductus arteriosus.